In Vitro Diagnostic (IVD) in Cardiology and Neurology Market Report 2026

The in vitro diagnostic (ivd) in cardiology and neurology market size has grown strongly in recent years. It will grow from $17.22 billion in 2025 to $18.71 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increasing incidence of neurological disorders, growth of hospital diagnostic infrastructure, advancements in immunoassay technologies, increased clinical awareness of early diagnosis.

The in vitro diagnostic (ivd) in cardiology and neurology market size is expected to see strong growth in the next few years. It will grow to $25.18 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to aging global population, rising demand for personalized diagnostics, expansion of point-of-care testing facilities, increasing healthcare expenditure in emerging markets, growing adoption of molecular diagnostics. Major trends in the forecast period include rising demand for early disease detection, increasing adoption of point-of-care cardiac and neuro tests, expansion of biomarker-based diagnostics, growing focus on preventive and predictive testing, integration of multi-parameter diagnostic panels.

The expansion of personalized medicine is expected to drive the growth of the in vitro diagnostic (IVD) market in cardiology and neurology going forward. Personalized medicine is a healthcare approach that customizes medical decisions, interventions, and treatments based on the individual characteristics of each patient. Its growth is supported by advancements in genomics, improved understanding of disease mechanisms, patient demand for tailored therapies, and regulatory encouragement. IVD tests in cardiology and neurology support personalized medicine by providing critical information on a patient’s genetic profile and disease status, enabling targeted treatment plans that enhance effectiveness and reduce risks. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit research organization, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. The 2023 approvals included seven oncology therapies and three treatments for other conditions. Therefore, the growing adoption of personalized medicines is driving the in vitro diagnostic (IVD) market in cardiology and neurology.

Major companies in the IVD market for cardiology and neurology are advancing diagnostics through AI-enabled innovations for early disease detection and risk assessment. AI-powered integrated epigenetic engines use machine-learning models combined with biomarker analysis to improve sensitivity and accuracy in detecting and monitoring cardiovascular diseases, addressing key factors in disease progression. For instance, in February 2023, Cardio Diagnostics Holdings Inc., a US-based biotechnology company, launched PrecisionCHD, an AI-driven blood test for the early detection of coronary heart disease (CHD). This test integrates epigenetic and genetic biomarkers with machine-learning algorithms, providing over 75% sensitivity for both men and women. It links a patient’s biomarker profile to modifiable risk factors such as smoking, diabetes, hypertension, and high cholesterol. PrecisionCHD offers a non-invasive alternative to exercise stress tests or angiograms, with blood samples collected in-office or at home.

In March 2024, Beckman Coulter, a US-based laboratory diagnostics company, expanded its partnership with Fujirebio, a Japan-based firm, to advance neurodegenerative disease assays. The collaboration aims to combine expertise in laboratory diagnostics and neurological biomarkers to develop, manufacture, and promote the clinical adoption of innovative assays for diagnosing neurodegenerative conditions. This partnership is expected to improve patient outcomes by enabling more accurate and timely diagnostics.

Major companies operating in the in vitro diagnostic (ivd) in cardiology and neurology market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson And Company, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., Beckman Coulter Inc., Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Instrumentation Laboratory, bioMérieux SA, Natera, Inc., Randox Laboratories Ltd., Fulgent Genetics Inc., DiaSorin S.p.A., Oxford Nanopore Technologies, Fujirebio Diagnostics Inc., Adaptive Biotechnologies, Biocartis Group NV, Agena Bioscience.

North America was the largest region in the in vitro diagnostic (IVD) in cardiology and neurology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the in vitro diagnostic (ivd) in cardiology and neurology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have introduced cost pressures in the in vitro diagnostic in cardiology and neurology market by increasing prices of diagnostic instruments, reagents, and molecular testing components. These impacts are most visible in reagent-intensive and instrument-heavy segments, particularly across asia-pacific and europe, where cross-border sourcing of diagnostic materials is high. Elevated import costs have affected procurement budgets of hospitals and clinical laboratories. However, tariffs are also encouraging localized manufacturing, regional supply chain development, and strategic partnerships, supporting long-term market stability and innovation.

The in vitro diagnostic (ivd) in cardiology and neurology market research report is one of a series of new reports that provides in vitro diagnostic (ivd) in cardiology and neurology market statistics, including in vitro diagnostic (ivd) in cardiology and neurology industry global market size, regional shares, competitors with a in vitro diagnostic (ivd) in cardiology and neurology market share, detailed in vitro diagnostic (ivd) in cardiology and neurology market segments, market trends and opportunities, and any further data you may need to thrive in the in vitro diagnostic (ivd) in cardiology and neurology industry. This in vitro diagnostic (ivd) in cardiology and neurology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In vitro diagnostic (IVD) in cardiology and neurology encompasses medical tests conducted on samples such as blood, urine, or tissue outside the body to detect and monitor cardiovascular and neurological conditions. These tests are essential for early disease detection, ongoing monitoring, and guiding treatment decisions for conditions such as heart disease, stroke, Alzheimer’s disease, and other related disorders. IVD provides timely diagnostic insights that support effective patient management and improve clinical outcomes in cardiology and neurology.

The primary products in the IVD market for cardiology and neurology include instruments, reagents and consumables, and software and services. Instruments refer to the equipment and devices used to perform diagnostic tests and analyze patient samples in laboratory environments. Key technologies involved include immunoassays, molecular diagnostics, hematology, and other methods, with end users such as hospitals, clinical laboratories, and diagnostic centers.

The in vitro diagnostic (IVD) in cardiology and neurology market consists of revenues earned by entities by providing services such as laboratory testing, point-of-care testing, molecular diagnostics, and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vitro diagnostic (IVD) in cardiology and neurology market also includes sales of laboratory testing, point-of-care testing, molecular diagnostics, and biomarker testing. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.